Antibody–Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond—A 2023 Review

por Xiao, Tian, Ali, Sanji, Mata, Danilo Giffoni M. M., Lohmann, Ana Elisa, Blanchette, Phillip S.
Publicado 2023

Programmed Cell Death Protein 1 Inhibitors and MET Targeted Therapies in NSCLC With MET Exon 14 Skipping Mutations: Efficacy and Toxicity as Sequential Therapies

por Lau, Sally C.M., Perdrizet, Kirstin, Fung, Andrea S., Mata, Danilo Giffoni M.M., Weiss, Jessica, Holzapfel, Nick, Liu, Geoffrey, Bradbury, Penelope A., Shepherd, Frances A., Sacher, Adrian G., Feilotter, Harriet, Sheffield, Brandon, Hwang, David, Tsao, Ming Sound, Cheng, Susanna, Cheema, Parneet, Leighl, Natasha B.
Publicado 2023